Bromotheophylline API Manufacturers

General Description:

Bromotheophylline, identified by CAS number 10381-75-6, is a notable compound with significant therapeutic applications. Bromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome. Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980. It is also approved by Health Canada to be used alone or in combination with in OTC products.

Indications:

This drug is primarily indicated for: Bromotheophylline is used as a diuretic and also, in combination with , it is used for the relief of temporary water weight gain, bloating, swelling and full feeling associated with the premenstrual and menstrual periods. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Bromotheophylline undergoes metabolic processing primarily in: This pharmacokinetic property has not been determined. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Bromotheophylline are crucial for its therapeutic efficacy: When administered after one single oral dosage, bromotheophylline is rapidly absorbed and it reaches a maximal plasma concentration of 2.5 mg/L in 0.78 hours. The mean residence time is registered to be of 12 hours with an AUC in the first 8 hours of 27 mg.h/L. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Bromotheophylline is an important consideration for its dosing schedule: The apparent elimination half-life is registered to be 21.35 hours. This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Bromotheophylline exhibits a strong affinity for binding with plasma proteins: This pharmacokinetic property has not been determined. This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Bromotheophylline from the body primarily occurs through: This pharmacokinetic property has not been determined. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Bromotheophylline is distributed throughout the body with a volume of distribution of: This pharmacokinetic property has not been determined. This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Bromotheophylline is a critical factor in determining its safe and effective dosage: This pharmacokinetic property has not been determined. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Bromotheophylline exerts its therapeutic effects through: Bromotheophylline diuretic action will produce an immediate increase in urination frequency. This effect aids in the relief of bloating and menstrual pain. This diuretic function is performed by the an increase in glomerular filtration and a potential effect in the tubular reabsorption as it is established that the administration of these agents produce a rise in the urinary concentration of sodium a chloride and thus, an increase in their rates of excretion. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Bromotheophylline functions by: Bromotheophylline is part of the group of the xanthines. As part of this group, it is thought that bromotheophylline increases the permeability of the renal tubule, increases glomerular filtration rate and inhibits the sodium reabsorption in the proximal tubule. It is thought but not confirmed that pamabrom as a mixture seems to have an additional mechanism of action in which the presence of 2-amino-2-methyl-1-propanol produces the suppression of the antidiuretic hormone in the posterior pituitary gland. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Categories:

Bromotheophylline is categorized under the following therapeutic classes: Alcohols, Alkaloids, Amines, Amino Alcohols, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Diuretics, Drugs for Obstructive Airway Diseases, Heterocyclic Compounds, Fused-Ring, Pharmaceutical Preparations, Propanols, Purines, Purinones, Xanthine derivatives. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Bromotheophylline include:

• Water Solubility: Soluble
• Melting Point: 295-316 ºC
• Boiling Point: Decomposes at 300 ºC
• pKa: 5.45